Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.

Abstract

We evaluated pomalidomide with prednisone for myelofibrosis (MF) with significant anemia (hemoglobin < 10 g/dL). Patients (n = 29; 18 RBC-transfusion dependent) received 0.5mg pomalidomide daily in continuous 28-day cycles with prednisone given for the first 3 cycles only. Six (21%) patients responded (median response duration 11.4 months), including four who achieved RBC-transfusion-independence per the Delphi criteria and two who achieved clinical improvement (in platelets and spleen, respectively) per the International Working Group for Myelofibrosis Research and Treatment criteria. Grade 3 toxicity occurred in 1 patient (fatigue). Pomalidomide with prednisone is safe therapy with modest activity in patients with MF and anemia. ClinicalTrials.gov Identifier: NCT00946270.

• Authors: Naval Daver, Aditi Shastri, Tapan Kadia, Kate Newberry, Naveen Pemmaraju, Elias Jabbour, Linghsa Zhou, Sherry Pierce, Jorge Cortes, Hagop Kantarjian, Srdan Verstovsek
• Journal: Leukemia research (Leuk Res) Vol. 38 Issue 9 Pg. 1126-9 (Sep 2014) ISSN: 1873-5835 [Electronic] England
• PMID: 25047979 (Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural)
• Copyright: Published by Elsevier Ltd.

Chemical References

• Thalidomide
• pomalidomide
• Prednisone

Topics

• Aged
• Aged, 80 and over
• Anemia (complications, drug therapy, mortality)
• Drug Administration Schedule
• Drug Therapy, Combination
• Female
• Humans
• Male
• Middle Aged
• Prednisone (administration & dosage)
• Primary Myelofibrosis (complications, drug therapy, mortality)
• Survival Analysis
• Thalidomide (administration & dosage, analogs & derivatives)
• Treatment Outcome